STAG2 and myelodysplastic syndrome: We first compared outcomes for STAG2-mutant MDS to cohesin-WT MDS in which STAG2 conferred a poor risk at a median OS of 30.3 versus 58.9 months (HR: 1.44, 95% CI 1.17–1.78, p < 0.001, combined cohort, Supplementary Fig. 9).